|Place of Origin:||China|
|Model Number:||CAS 71125-38-7|
|Minimum Order Quantity:||1g|
|Packaging Details:||as your required|
|Delivery Time:||3-7 working days|
|Payment Terms:||Western Union, MoneyGram, T/T, Bitcoin|
|Supply Ability:||5 KG / month|
|Trade Names::||Mobic||Water Solubility:||DMSO: Soluble|
pharmaceutical raw material,
raw materials for pharmaceutical products
Meloxicam Pharmaceutical Intermediates Nonsteroidal Anti-inflammatory Drug (NSAID)
Biological half-life:20 hours
Systematic (IUPAC) name:4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and fever reducer effects. It is a derivative of oxicam, closely related to piroxicam, and falls in the enolic acid group of NSAIDs. It was developed by Boehringer-Ingelheim. Meloxicam starts to relieve pain about 30–60 minutes after administration.
Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID).If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
Meloxicam use can result in gastrointestinal toxicity and bleeding, headaches, rash, and very dark or black stool (a sign of intestinal bleeding). Like other NSAIDs, its use is associated with an increased risk of cardiovascular events such as heart attack and stroke.It has fewer gastrointestinal side effects thandiclofenac, piroxicam,naproxen, and perhaps all other NSAIDs which are not COX-2 selective.Although meloxicam inhibits thromboxane A, it does not appear to do so at levels that would interfere withplatelet function.
A pooled analysis of randomized, controlled studies of meloxicam therapy of up to 60 days duration found that meloxicam was associated with a statistically significantly lower number of thromboemboliccomplications than the NSAID diclofenac (0.2% versus 0.8% respectively) but a similar incidence of thromboembolic events to naproxen and piroxicam.
Cardiovascular side effects
Persons with hypertension, high cholesterol, or diabetes are at risk for cardiovascular side effects. Persons with family history of heart disease, heart attack, or stroke must tell their treating physician as the potential for serious cardiovascular side effects is significant.
|Meloxicam Chemical Properties|
|Stability:||Stable. Incompatible with strong oxidizing agents|
|RIDADR||UN 2811 6.1/PG 3|
Any needs, please contact me